[1]杨明威,王孝深,王凡,等.顺铂单周与三周方案同期联合调强放射治疗局部晚期鼻咽癌的不良反应与疗效的比较[J].国际放射医学核医学杂志,2018,(5):397-402.[doi:10.3760/cma.j.issn.1673-4114.2018.05.002]
　Yang Mingwei,Wang Xiaoshen,Wang Fan,et al.Comparison of toxicities and treatment outcome of weekly and triweekly cisplatin concurrent with intensity-modulated radiotherapy for locally advanced nasopharyngeal carcinoma[J].International Journal of Radiation Medicine and Nuclear Medicine,2018,(5):397-402.[doi:10.3760/cma.j.issn.1673-4114.2018.05.002]
点击复制

顺铂单周与三周方案同期联合调强放射治疗局部晚期鼻咽癌的不良反应与疗效的比较(/HTML)
分享到：

《国际放射医学核医学杂志》[ISSN:1673-4114/CN:12-1381/R]

卷:
期数:
2018年第5期
页码:
397-402
栏目:
临床研究
出版日期:
2018-10-01

文章信息/Info

Title:
Comparison of toxicities and treatment outcome of weekly and triweekly cisplatin concurrent with intensity-modulated radiotherapy for locally advanced nasopharyngeal carcinoma
作者:
杨明威1;  王孝深2;  王凡1;  杨林1;  张帆1;  汪浩1;  吕银1;  吴齐兵1;  童铸廷1
1. 230000 合肥, 安徽医科大学第一附属医院肿瘤放疗科;
2. 200000 上海, 复旦大学附属肿瘤医院肿瘤放疗科
Author(s):
Yang Mingwei1;  Wang Xiaoshen2;  Wang Fan1;  Yang Lin1;  Zhang Fan1;  Wang Hao1;  Lyu Yin1;  Wu Qibin1;  Tong Zhuting1
1. Department of Radiation Oncology, the First Affiliated Hospital of Anhui Medical University, Hefei 230000, China;
2. Department of Radiation Oncology, Tumor Hospital of Fudan University, Shanghai 200000, China
关键词:
鼻咽肿瘤; 放射疗法; 调强适形; 药物疗法; 顺铂
Keywords:
Nasopharyngeal neoplasms;  Radiotherapy;  intensity modulated;  Drug cherapy;  Cisplatin
DOI:
10.3760/cma.j.issn.1673-4114.2018.05.002
摘要:
目的 比较顺铂单周或三周治疗方案同步调强放疗对局部晚期鼻咽癌患者的血液学、黏膜不良反应及疗效的差异。方法 回顾性分析2009年10月至2013年12月收集的148例初治局部晚期鼻咽癌患者资料，所有患者均接受2周期诱导化疗后行调强放疗联合顺铂单药治疗模式，其中75例患者接受顺铂单周治疗方案，73例患者接受顺铂三周治疗方案。采用χ2检验比较两组的血液学不良反应、黏膜不良反应、肿瘤缓解率和预后的差异。两组间的生存率进行Kaplan-Meier法计算并行log-rank检验。结果 顺铂单周组及顺铂三周组化疗的平均治疗周期数为3.64个（20%达5个周期）和1.86个（86%达2个周期）。顺铂单周组对比顺铂三周组的Ⅰ、Ⅱ度白细胞减少的患者比例的差异均有统计学意义（31% vs.51%、35% vs.19%，χ2=6.150、4.500，均P<0.05）；其他血液学不良反应两组间的差异均无统计学意义。两组黏膜反应差异无统计学意义（χ2=0.137，P=0.934）。放疗结束后6个月顺铂单周与顺铂三周组肿瘤的完全缓解率分别为98.7%和98.6%，单周组和三周组5年生存率分别为77.84%和79.97%，两组间差异无统计学意义（χ2=3.78，P=0.059）；5年无病生存率分别为67.96%和69.10%（χ2=1.25，P=0.27），5年无局部复发生存率分别为88.76%和86.96%（χ2=0.43，P=0.56），5年无区域复发生存率分别为91.49%和90.84%（χ2=0.18，P=0.67），5年无远处转移生存率分别为77.86%和78.90%（χ2=0.31，P=0.56），两组间差异均无统计学意义。结论 局部晚期鼻咽癌在接受2周期诱导化疗后，顺铂三周联合放疗方案在血液学不良反应方面优于顺铂单周治疗方案，两组在黏膜相关不良反应以及疗效上未见显著差异，顺铂三周组较顺铂单周组具有较好的治疗依从性。
Abstract:
Objective To evaluate the rates of hematologic and mucosal toxicities and treatment outcome of a weekly cisplatin (QW) and triweekly cisplatin (Q3W) regimens concurrent with intensity-modulated radiotherapy (IMRT) for local regionally advanced nasopharyngeal carcinoma (NPC). Methods A total of 148 patients with biopsy-proven NPC staged at Ⅲ to IVB were retrospectively enrolled from October 2009 to December 2013 in this study. Among all patients, 75 and 73 received QW and Q3W cisplatin chemotherapy regimens concurrent with IMRT, respectively. All patients received neoadjuvant chemotherapy. The χ2-test was used to compare clinical characteristics of the patients and hematologic and mucosal toxicities. Tumor response and survival rates were estimated through the Kaplan-Meier method with log-rank test. Results The mean total cycles of the cisplatin regimen was 3.64 in the QW group with 15 patients (20%) reaching five cycles and 1.86 in the Q3W group with 86% reaching two cycles. Grades 1, 2 leucopenia were 31% vs. 51% and 35% vs. 19%, respectively, in the QW and Q3W groups. The two groups showed significant differences in Grades 1 and 2 leucopenia (χ2=6.150, 4.500, both P<0.05) but not for other hematological toxicities and mucositis (χ2=0.137, P=0.934). The complete remission rates at 6 months after radiotherapy for the QW and QW3 groups were 98.7% and 98.6%, respectively. The 5-year estimated overall survival, disease-free survival, local recurrence-free survival, regional recurrence-free survival, and distant metastasis-free survival rates of the QW and Q3W groups were 77.84% vs. 79.97% (χ2=3.78, P=0.059), 67.96% vs. 69.10% (χ2=1.25, P=0.27), 88.76% vs. 86.96% (χ2=0.43, P=0.56), 91.49% vs. 90.84% (χ2=0.18, P=0.67), and 77.86% vs. 78.90% (χ2=0.31, P=0.56), respectively, and were not significantly different between the two groups. Conclusions Hematological toxicities associated with the QW3 regimen concurrent with IMRT for locally advanced NPC were milder than those associated with the QW weekly regimen. Mucositis and treatment outcome did not significantly differ between the two groups. Patients showed better compliance with the Q3W regimen than with the QW regimen.

参考文献/References:

[1] Al-Sarraf M, LeBlanc M, Giri PG, et al. Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer:phase Ⅲ randomized Intergroup study 0099[J]. J Clin Oncol, 1998, 16 (4):1310-1317. DOI:10.1200/JCO.1998.16.4.1310.
[2] Chan AT, Leung SF, Ngan RK, et al. Overall survival after concurrent cisplatin-radiotherapy compared with radiotherapy alone in locoregionally advanced nasopharyngeal carcinoma[J]. J Natl Cancer Inst, 2005, 97 (7):536-539. DOI:10.1093/jnci/dji084.
[3] Shah BA, Qureshi MM, Jalisi S, et al. Analysis of decision making at a multidisciplinary head and neck tumor board incorporating evidence-based National Cancer Comprehensive Network (NCCN) guidelines[J]. Pract Radiat Oncol, 2016, 6 (4):248-254. DOI:10.1016/j.prro.2015.11.006.
[4] Pignon JP, le Maitre A, Maillard E, et al. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC):an update on 93 randomised trials and 17, 346 patients[J]. Radiother Oncol, 2009, 92 (1):4-14. DOI:10.1016/j.radonc.2009.04.014.
[5] Blanchard P, Bourhis J, Lacas B, et al. Taxane-cisplatin-fluorouracil as induction chemotherapy in locally advanced head and neck cancers:an individual patient data meta-analysis of the meta-analysis of chemotherapy in head and neck cancer group[J]. J Clin Oncol, 2013, 31 (23):2854-2860. DOI:10.1200/JCO.2012. 47.7802.
[6] Hui EP, Ma BB, Leung SF, et al. Randomized phase Ⅱ trial of concurrent cisplatin-radiotherapy with or without neoadjuvant docetaxel and cisplatin in advanced nasopharyngeal carcinoma[J]. J Clin Oncol, 2009, 27 (2):242-249. DOI:10.1200/JCO.2008. 18. 1545.
[7] Lee N, Harris J, Garden AS, et al. Intensity-modulated radiation therapy with or without chemotherapy for nasopharyngeal carcinoma:radiation therapy oncology group phase Ⅱ trial 0225[J]. J Clin Oncol, 2009, 27 (22):3684-3690. DOI:10.1200/JCO.2008.19.9109.
[8] Miller AB, Hoogstraten B, Staquet M, et al. Reporting results of cancer treatment[J]. Cancer, 1981, 47 (1):207-214.
[9] Cox JD, Stetz J, Pajak TF. Toxicity criteria of the Radiation Therapy Oncolog y Group (RTOG) and the European organization for research and treatment of cancer (EORTC)[J]. Int J Radiat Oncol Biol Phys, 1995, 31 (5):1341-1346.
[10] Lin JC, Jan JS, Hsu CY, et al. Phase Ⅲ study of concurrent chemoradiotherapy versus radiotherapy alone for advanced nasopharyngeal carcinoma:positive effect on overall and progression-free survival[J]. J Clin Oncol, 2003, 21 (4):631-637. DOI:10.1200/JCO.2003.06.158.
[11] Chan AT, Teo PM, Ngan RK, et al. Concurrent chemotherapy-radiotherapy compared with radiotherapy alone in locoregionally advanced nasopharyngeal carcinoma:progression-free survival analysis of a phase Ⅲ randomized trial[J]. J Clin Oncol, 2002, 20 (8):2038-2044. DOI:10.1200/JCO.2002.08.149.
[12] Jagdis A, Laskin J, Hao D, et al. Dose delivery analysis of weekly versus 3-weekly cisplatin concurrent with radiation therapy for locally advanced nasopharyngeal carcinoma (NPC)[J]. Am J Clin Oncol, 2014, 37 (1):63-69. DOI:10.1097/COC.0b013e31826b9b1a.
[13] Ho KF, Swindell R, Brammer CV. Dose intensity comparison between weekly and 3-weekly Cisplatin delivered concurrently with radical radiotherapy for head and neck cancer:a retrospective comparison from New Cross Hospital, Wolverhampton, UK[J]. Acta Oncol, 2008, 47 (8):1513-1518. DOI:10.1080/02841860701846160.
[14] Lee AW, Tung SY, Ngan RK, et al. Factors contributing to the efficacy of concurrent-adjuvant chemotherapy for locoregionally advanced nasopharyngeal carcinoma:combined analyses of NPC-9901 and NPC-9902 Trials[J]. Eur J Cancer, 2011, 47 (5):656-666. DOI:10.1016/j.ejca.2010.10.026.
[15] Loong HH, Ma BB, Leung SF, et al. Prognostic significance of the total dose of cisplatin administered during concurrent chemoradiotherapy in patients with locoregionally advanced nasopharyngeal carcinoma[J]. Radiother Oncol, 2012, 104 (3):300-304. DOI:10.1016/j.radonc.2011.12.022.
[16] Meng DF, Sun R, Peng LX, et al. A comparison of weekly versus 3-weekly cisplatin during concurrent chemoradiotherapy for locoregionally advanced nasopharyngeal carcinoma using intensity modulated radiation therapy:a matched study[J]. J Cancer, 2018, 9 (1):92-99. DOI:10.7150/jca.21357.
[17] Kong L, Hu C, Niu X, et al. Neoadjuvant chemotherapy followed by concurrent chemoradiation for locoregionally advanced nasopharyngeal carcinoma:interim results from 2 prospective phase 2 clinical trials[J]. Cancer, 2013, 119 (23):4111-4118. DOI:10.1002/cncr.28324.
[18] Zhong YH, Dai J, Wang XY, et al. Phase Ⅱ trial of neoadjuvant docetaxel and cisplatin followed by intensity-modulated radiotherapy with concurrent cisplatin in locally advanced nasopharyngeal carcinoma[J]. Cancer Chemother Pharmacol, 2013, 71 (6):1577-1583. DOI:10.1007/s00280-013-2157-2.
[19] Ou X, Zhou X, Shi Q, et al. Treatment outcomes and late toxicities of 869 patients with nasopharyngeal carcinoma treated with definitive intensity modulated radiation therapy:new insight into the value of total dose of cisplatin and radiation boost[J]. Oncotarget, 2015, 6 (35):38381-38397. DOI:10.18632/oncotarget.5420.
[20] Sun X, Su S, Chen C, et al. Long-term outcomes of intensitymodulated radiotherapy for 868 patients with nasopharyngeal carcinoma:an analysis of survival and treatment toxicities[J]. Radiother Oncol, 2014, 110 (3):398-403. DOI:10.1016/j.radonc.2013.10.020.

相似文献/References:

[1]李景涛,邓垒,张文珏,等.广泛期小细胞肺癌胸部IMRT后发生放射性肺炎的危险因素分析[J].国际放射医学核医学杂志,2016,40(2):100.[doi:10.3760/cma.j.issn.1673-4114.2016.02.003]
　Li Jingtao,Deng Lei,Zhang Wenjue,et al.Risk factor analysis for predicting radiation pneumonitis in extensive stage small cell lung cancer patients receiving IMRT thoracic radiotherapy[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(5):100.[doi:10.3760/cma.j.issn.1673-4114.2016.02.003]
[2]刘佳,高刚,朴春南,等.调节肿瘤放射敏感性的miRNAs研究进展[J].国际放射医学核医学杂志,2016,40(2):159.[doi:10.3760/cma.j.issn.1673-4114.2016.02.015]
　Liu Jia,Gao Gang,Piao Chunnan,et al.Progress of microRNAs in regulating tumor radiation sensitivity[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(5):159.[doi:10.3760/cma.j.issn.1673-4114.2016.02.015]
[3]陈晓艳,张江虹,邵春林.STAT3与辐射敏感相关性的研究进展[J].国际放射医学核医学杂志,2016,40(3):191.[doi:10.3760/cma.j.issn.1673-4114.2016.03.007]
　Chen Xiaoyan,Jianghong,Shao Chunlin.Research progresses of correlation between STAT3 and radiosensitivity[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(5):191.[doi:10.3760/cma.j.issn.1673-4114.2016.03.007]
[4]赵德云,李百龙.植物提取物防治放射性肺损伤的现状与展望[J].国际放射医学核医学杂志,2016,40(3):208.[doi:10.3760/cma.j.issn.1673-4114.2016.03.010]
　Zhao Deyun,Li Bailong.Protective and therapeutic effects of plant extracts on radiation-induced lung injury:present status and future prospects[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(5):208.[doi:10.3760/cma.j.issn.1673-4114.2016.03.010]
[5]田琦,蒋宁一,郑丽.265例精细个体化131I治疗Graves甲亢的疗效观察[J].国际放射医学核医学杂志,2016,40(4):259.[doi:10.3760/cma.j.issn.1673-4114.2016.04.004]
　Tian Qi,Jiang Ningyi,Zheng Li.Therapeutic effect of fine individual 131I treatment on Graves disease hyperthyroidism[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(5):259.[doi:10.3760/cma.j.issn.1673-4114.2016.04.004]
[6]邓大平,卢峰,孙洪强,等.颅脑肿瘤放射治疗时射野外器官吸收剂量体模法测量与分析[J].国际放射医学核医学杂志,2016,40(4):272.[doi:10.3760/cma.j.issn.1673-4114.2016.04.007]
　Deng Daping,Lu Feng,Sun Hongqiang,et al.Test and analysis of out-of-field organ dose in intracranial tumor radiotherapy using phantom[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(5):272.[doi:10.3760/cma.j.issn.1673-4114.2016.04.007]
[7]赵舒怡,储小飞,樊赛军.血清肿瘤标志物与肿瘤放疗疗效评估的研究进展[J].国际放射医学核医学杂志,2015,39(5):427.[doi:10. 3760 / cma. j. issn. 1673-4114. 2015. 05. 018]
　zhao shuyi,chu xiaofei,fan saijun..progression of study on serum tumor markers in evaluation of tumor radiotherapy[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(5):427.[doi:10. 3760 / cma. j. issn. 1673-4114. 2015. 05. 018]
[8]赵徵鑫,翟贺争,张文艺,等.质子重离子治疗肿瘤的进展[J].国际放射医学核医学杂志,2016,40(5):384.[doi:10.3760/cma.j.issn.1673-4114.2016.05.010]
　Zhao Zhixin,Zhai Hezheng,Zhang Wenyi,et al.Development of proton heavy ion in tumor therapy[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(5):384.[doi:10.3760/cma.j.issn.1673-4114.2016.05.010]
[9]段永璇,邹晓艳,段秀梅,等.数据解析在肿瘤放射治疗中的应用[J].国际放射医学核医学杂志,2015,39(6):505.[doi:10.3760/cma.j.issn.1673-4114.2015.06.015]
　Duan Yongxuan,Zou Xiaoyan,Duan Xiumei,et al.Data analysis in the field of tumor radiation therapy[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(5):505.[doi:10.3760/cma.j.issn.1673-4114.2015.06.015]
[10]贾立立,孟粹达,刘晓冬,等.头颈部肿瘤放疗中转化医学相关机制的研究进展[J].国际放射医学核医学杂志,2015,39(3):247.[doi:10.3760/cma.j.issn.1673-4114.2015.03.013]
　Jia Lili,Meng Cuida,Liu Xiaodong,et al.Development in translational medicine-related mechanisms of radiotherapy for head and neck cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(5):247.[doi:10.3760/cma.j.issn.1673-4114.2015.03.013]
[11]冯彦林,王颖,张宁,等.鼻咽癌不同模式放疗后的PET/CT早期评估价值的研究[J].国际放射医学核医学杂志,2014,38(4):223.[doi:10.3760/cma.j.issn.1673-4114.2014.04.004]
　Feng Yanlin,Wang Ying,Zhang Ning,et al.Early evaluation value of PET/CT in nasopharyngeal carcinoma after different models of radiotherapy[J].International Journal of Radiation Medicine and Nuclear Medicine,2014,38(5):223.[doi:10.3760/cma.j.issn.1673-4114.2014.04.004]
[12]陈凤华,李东坡,郭萍,等.整体护理对鼻咽癌患者放疗期间口腔黏膜损伤防治的作用[J].国际放射医学核医学杂志,2012,36(3):176.[doi:10.3760/cma.j.issn.1673-4114.2012.03.014]
　CHEN Feng-hua,LI Dong-po,GUO Ping,et al.Effects of holistic nursing on protection and control of nasopharyngeal carcinomapatient’ oral mucosa damage during radiotherapy[J].International Journal of Radiation Medicine and Nuclear Medicine,2012,36(5):176.[doi:10.3760/cma.j.issn.1673-4114.2012.03.014]
[13]王颖,冯彦林.18F-FDG PET-CT在鼻咽癌靶区勾画及推量照射研究中的价值[J].国际放射医学核医学杂志,2011,35(2):84.[doi:10.3760/cma.j.issn.1673-4114.2011.02.005]
　WANG Ying,FENG Yan-lin.Value of 18F-FDG PET-CT in nasopharyngeal carcinoma target delineation and radiotherapy boost[J].International Journal of Radiation Medicine and Nuclear Medicine,2011,35(5):84.[doi:10.3760/cma.j.issn.1673-4114.2011.02.005]
[14]邱新峰,刘强.鼻咽癌放疗致放射性脑损伤的临床分析[J].国际放射医学核医学杂志,2008,32(3):191.
[15]何小江,黄劲雄,俞浩,等.腮腺动态显像评价鼻咽癌放疗对腮腺功能的影响[J].国际放射医学核医学杂志,2008,32(5):272.
　HE Xiao-jiang,HUANG Jin-xiong,YU Hao,et al.Evaluation of parotid function using dynamic parotid scintigraphy in nasopharyngeal carcinoma patients treated with external beam radiation therapy[J].International Journal of Radiation Medicine and Nuclear Medicine,2008,32(5):272.
[16]苏新辉,吴华,黄劲雄,等.99mTc-HL91乏氧显像评价30例鼻咽癌患者放疗疗效[J].国际放射医学核医学杂志,2008,32(2):99.
　SU Xin-hui,WU Hua,HUANG Jing-xiong,et al.The application of 99mTc-HL91 hypoxic imaging in detecting radiotherapy response in 30 patients with nasopharyngeal carcinoma[J].International Journal of Radiation Medicine and Nuclear Medicine,2008,32(5):99.
[17]鲁杰,刘强.老年鼻咽癌115例放疗疗效评价[J].国际放射医学核医学杂志,2008,32(4):254.
[18]薛咏,刘生,张弘,等.鼻咽癌乏氧程度与放疗中期肿瘤退缩关系的初步研究[J].国际放射医学核医学杂志,2007,31(4):232.
　XUE Yong,LIU Sheng,ZHANG Hong,et al.The relationship between tumor regression degree and its hypoxia degree in patients with nasopharyngeal carcinoma[J].International Journal of Radiation Medicine and Nuclear Medicine,2007,31(5):232.

备注/Memo

备注/Memo:
收稿日期:2018-01-06。
通讯作者:王孝深,Email:ruijin702@163.com
更新日期/Last Update: 2018-10-01